News headlines about Biohaven Pharmaceutical (NYSE:BHVN) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.0440752834935 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern’s scoring:

BHVN has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. BidaskClub upgraded Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. Piper Jaffray Companies reiterated a “buy” rating and set a $54.00 target price on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 12th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 target price (up from $30.00) on shares of Biohaven Pharmaceutical in a research report on Wednesday, September 13th. Finally, Morgan Stanley upped their price objective on Biohaven Pharmaceutical from $28.00 to $47.00 and gave the stock an “overweight” rating in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $40.80.

Shares of Biohaven Pharmaceutical (BHVN) opened at $22.58 on Friday. Biohaven Pharmaceutical has a 1 year low of $17.00 and a 1 year high of $39.51.

In other Biohaven Pharmaceutical news, Director Gregory Bailey sold 9,970 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $25.48, for a total value of $254,035.60. Following the completion of the transaction, the director now owns 1,262,759 shares of the company’s stock, valued at approximately $32,175,099.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Kimberly Gentile sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.28, for a total value of $146,400.00. Following the completion of the transaction, the vice president now directly owns 5,000 shares of the company’s stock, valued at approximately $146,400. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 434,131 shares of company stock valued at $11,901,751.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/biohaven-pharmaceutical-bhvn-given-daily-coverage-optimism-score-of-0-09/1741114.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.